1. Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides
- Author
-
Hannah Pendergraff, Christian Weile, Jonas Vikeså, Charlotte Øverup, Troels Koch, Steffen Schmidt, and Marie W. Lindholm
- Subjects
0301 basic medicine ,Biodistribution ,Oligonucleotides ,Enzyme-Linked Immunosorbent Assay ,Biochemistry ,Nucleobase ,03 medical and health sciences ,0302 clinical medicine ,Drug Discovery ,Genetics ,medicine ,Humans ,Tissue Distribution ,Molecular Targeted Therapy ,Locked nucleic acid ,Molecular Biology ,biodistribution ,Cell Nucleus ,Gene knockdown ,Oligonucleotide ,Chemistry ,Drug discovery ,Oligonucleotides, Antisense ,Original Papers ,quantification ,030104 developmental biology ,medicine.anatomical_structure ,LNA ,030220 oncology & carcinogenesis ,Molecular Medicine ,Cell fractionation ,Nucleus - Abstract
Methods for the quantification of antisense oligonucleotides (AONs) provide insightful information on biodistribution and intracellular trafficking. However, the established methods have not provided information on the absolute number of molecules in subcellular compartments or about how many AONs are needed for target gene reduction for unconjugated AONs. We have developed a new method for nuclear AON quantification that enables us to determine the absolute number of AONs per nucleus without relying on AON conjugates such as fluorophores that may alter AON distribution. This study describes an alternative and label-free method using subcellular fractionation, nucleus counting, and locked nucleic acid (LNA) sandwich enzyme-linked immunosorbent assay to quantify absolute numbers of oligonucleotides in nuclei. Our findings show compound variability (diversity) by which 247,000-693,000 LNAs/nuclei results in similar target reduction for different compounds. This method can be applied to any antisense drug discovery platform providing information on specific and clinically relevant AONs. Finally, this method can directly compare nuclear entry of AON with target gene knockdown for any compound design and nucleobase sequence, gene target, and phosphorothioate stereochemistry.
- Published
- 2019